Eli Lilly Total Non-Operating Income/Expense 2010-2024 | LLY
Eli Lilly annual/quarterly total non-operating income/expense history and growth rate from 2010 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
- Eli Lilly total non-operating income/expense for the quarter ending September 30, 2024 was $-2.764B, a 7.8% decline year-over-year.
- Eli Lilly total non-operating income/expense for the twelve months ending September 30, 2024 was $-0.274B, a 90.01% decline year-over-year.
- Eli Lilly annual total non-operating income/expense for 2023 was $0.097B, a 130.13% decline from 2022.
- Eli Lilly annual total non-operating income/expense for 2022 was $-0.321B, a 59.18% increase from 2021.
- Eli Lilly annual total non-operating income/expense for 2021 was $-0.202B, a 117.2% decline from 2020.
Eli Lilly Annual Total Non-Operating Income/Expense
(Millions of US $) |
| 2023 |
$97 |
| 2022 |
$-321 |
| 2021 |
$-202 |
| 2020 |
$1,172 |
| 2019 |
$292 |
| 2018 |
$146 |
| 2017 |
$302 |
| 2016 |
$113 |
| 2015 |
$101 |
| 2014 |
$341 |
| 2013 |
$519 |
| 2012 |
$674 |
| 2011 |
$-179 |
| 2010 |
$-5 |
| 2009 |
$-230 |
Eli Lilly Quarterly Total Non-Operating Income/Expense
(Millions of US $) |
| 2024-09-30 |
$-2,764 |
| 2024-06-30 |
$-633 |
| 2024-03-31 |
$27 |
| 2023-12-31 |
$3,096 |
| 2023-09-30 |
$-2,998 |
| 2023-06-30 |
$-37 |
| 2023-03-31 |
$36 |
| 2022-12-31 |
$260 |
| 2022-09-30 |
$-111 |
| 2022-06-30 |
$-119 |
| 2022-03-31 |
$-351 |
| 2021-12-31 |
$-77 |
| 2021-09-30 |
$-636 |
| 2021-06-30 |
$191 |
| 2021-03-31 |
$321 |
| 2020-12-31 |
$477 |
| 2020-09-30 |
$159 |
| 2020-06-30 |
$447 |
| 2020-03-31 |
$89 |
| 2019-12-31 |
$263 |
| 2019-09-30 |
$-25 |
| 2019-06-30 |
$-32 |
| 2019-03-31 |
$86 |
| 2018-12-31 |
$31 |
| 2018-09-30 |
$-2 |
| 2018-06-30 |
$47 |
| 2018-03-31 |
$70 |
| 2017-12-31 |
$113 |
| 2017-09-30 |
$50 |
| 2017-06-30 |
$60 |
| 2017-03-31 |
$78 |
| 2016-12-31 |
$213 |
| 2016-09-30 |
$27 |
| 2016-06-30 |
$21 |
| 2016-03-31 |
$-149 |
| 2015-12-31 |
$117 |
| 2015-09-30 |
$87 |
| 2015-06-30 |
$-196 |
| 2015-03-31 |
$93 |
| 2014-12-31 |
$205 |
| 2014-09-30 |
$57 |
| 2014-06-30 |
$54 |
| 2014-03-31 |
$25 |
| 2013-12-31 |
$31 |
| 2013-09-30 |
$-31 |
| 2013-06-30 |
$12 |
| 2013-03-31 |
$508 |
| 2012-12-31 |
$1 |
| 2012-09-30 |
$735 |
| 2012-06-30 |
$-17 |
| 2012-03-31 |
$-46 |
| 2011-12-31 |
$50 |
| 2011-09-30 |
$-83 |
| 2011-06-30 |
$-58 |
| 2011-03-31 |
$-88 |
| 2010-12-31 |
$74 |
| 2010-09-30 |
$-81 |
| 2010-06-30 |
$-46 |
| 2010-03-31 |
$48 |
| 2009-12-31 |
$587 |
| 2009-09-30 |
$-617 |
| 2009-06-30 |
$-129 |
| 2009-03-31 |
$-71 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$789.394B |
$34.124B |
|
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
|
